<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2176">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05132829</url>
  </required_header>
  <id_info>
    <org_study_id>21D.746</org_study_id>
    <nct_id>NCT05132829</nct_id>
  </id_info>
  <brief_title>Azithromycin to Improve Latency in Exam Indicated Cerclage Control Trial</brief_title>
  <acronym>ALEC</acronym>
  <official_title>Azithromycin to Improve Latency in Exam Indicated Cerclage: a Randomized Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Azithromycin is an antibiotic that is effective against bacteria that been associated with&#xD;
      preterm birth (PTB). The purpose of this study is to evaluate if the addition of azithromycin&#xD;
      prior to exam indicated cerclage prolongs gestation. A cerclage is a suture placed in the&#xD;
      cervix to prolong gestation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preterm birth (PTB) continues to be a leading cause of neonatal morbidity and mortality. The&#xD;
      rate of spontaneous PTB (delivery before 37 weeks gestation) is one in ten pregnancies and a&#xD;
      history of prior preterm birth remains a risk factor for recurrence. The pathophysiology of&#xD;
      cervical insufficiency leading to PTB remains poorly understood.&#xD;
&#xD;
      While interventions for PTB prevention are limited, the American College of Obstetrics and&#xD;
      Gynecology (ACOG) supports the use of cervical cerclage. A physical exam indicated cerclage&#xD;
      may be placed in the setting of painless cervical dilation in the second trimester. The&#xD;
      cerclage is believed to provide mechanical support to a weakened cervix and promote the&#xD;
      cervical mucosal plug as a barrier to ascending infection.&#xD;
&#xD;
      While many aspects of cerclage use have been extensively studied, the use of antibiotics&#xD;
      prior to placement remains under evaluated. While antibiotic use is recommended during&#xD;
      cesarean section, preterm premature rupture of membranes (PPROM), and obstetric anal&#xD;
      sphincter injuries (OASIS), ACOG currently does not recommend perioperative antibiotics or&#xD;
      prophylactic tocolytics at the time of cerclage placement citing insufficient evidence.&#xD;
&#xD;
      Miller et al. performed a randomized controlled trial (RCT) showing an increased incidence of&#xD;
      pregnancy prolongation by at least 28 days among women who received indomethacin and&#xD;
      perioperative antibiotics in the setting of an exam indicated cerclage compared to those who&#xD;
      received no perioperative medications (92.3% vs 62.5%, p=0.01). Participants in the&#xD;
      experimental arm received cefazolin or clindamycin if they had a penicillin allergy.&#xD;
      Cefazolin is a first generation cephalosporin that has activity against gram positive cocci&#xD;
      and gram negative rods and is commonly used for surgical prophylaxis. Clindamycin is a&#xD;
      protein synthesis inhibitor and covers gram positive organisms and anaerobic bacteria, making&#xD;
      it an appropriate alternative in cases of penicillin allergy. The use of cefazolin&#xD;
      specifically with indomethacin has been studied retrospectively and showed a significant&#xD;
      improvement in gestational latency (adjusted relative risk [aRR] 1.21, 95% CI 1.05-1.40) and&#xD;
      birth weight (+489.8 grams, 95% CI 64.6-915.0).&#xD;
&#xD;
      The use of prolonged azithromycin with cerclage has been studied in a prospective, non-&#xD;
      randomized fashion. In this study, patients were given 500mg azithromycin for 3 days and this&#xD;
      was repeated every 10 days until 34 weeks. Patients who received this regimen and a cerclage&#xD;
      had lower PTB (65.7% vs 5.7%, p&lt;0.001) and reduced immediate fetal mortality (37.1% vs 0%,&#xD;
      p&lt;0.001).&#xD;
&#xD;
      The aim of our study is to determine if the addition of azithromycin prior to exam indicated&#xD;
      cerclage prolongs gestation. Azithromycin is a macrolide antibiotic that binds to the 50S&#xD;
      subunit of the bacterial ribosome and inhibits transpeptidation. It is effective against a&#xD;
      wide variety of bacteria, specifically mycoplasma which has been associated with preterm&#xD;
      birth. Azithromycin is currently used in obstetrics for patients undergoing nonelective&#xD;
      cesarean delivery and as part of latency antibiotics in the setting of PPROM.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">June 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gestational Latency Achieved Between Cerclage Placement and Time of Delivery</measure>
    <time_frame>24 weeks following cerclage placement</time_frame>
    <description>Mean gestational latency achieved Between Cerclage Placement and Time of Delivery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Preterm birth &lt;37 weeks, &lt;34 weeks, &lt;32 weeks, &lt;28 weeks, &lt;24 weeks</measure>
    <time_frame>at delivery following cerclage placement. Latest will occur 26 weeks following cerclage placement.</time_frame>
    <description>Preterm delivery stratified by gestational age at delivery in weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean gestational age at delivery</measure>
    <time_frame>at delivery following cerclage placement. Latest will occur 26 weeks following cerclage placement.</time_frame>
    <description>Measured in weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>chorioamnionitis</measure>
    <time_frame>at delivery following cerclage placement. Latest will occur 26 weeks following cerclage placement.</time_frame>
    <description>Histologic or clinical diagnosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>birth weight</measure>
    <time_frame>at delivery following cerclage placement. Latest will occur 26 weeks following cerclage placement.</time_frame>
    <description>measured in grams</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Admission to neonatal intensive care unit</measure>
    <time_frame>at delivery following cerclage placement. Latest will occur 26 weeks following cerclage placement.</time_frame>
    <description>If admitted, measured in days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal Morbidity and Mortality</measure>
    <time_frame>within 28 days of delivery</time_frame>
    <description>including apgars, Respiratory Distress Syndrome, Bronchopulmonary dysplasia, Retinopathy of prematurity, Intraventricular hemorrhage (IVH) (grade 3 or 4), patent ductus arteriosus, and neonatal death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cervicovaginal cytokine analysis</measure>
    <time_frame>Cerclage placement and 1-4 weeks after</time_frame>
    <description>Measurement of proinflammatory cytokines in pg/ml (IL-1B, IL-2, IL-4, IL-6, IL-8, IL-8, IL-10, G-CSF, GM-CSF, MCP-1, TNF-a, IFN-g, CCL5, VEGF, ICAM-1) from cervicovaginal fluid at the time of cerclage placement and at follow up 1-4 weeks after placement</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Preterm Birth</condition>
  <condition>Obstetric Labor, Premature</condition>
  <condition>Obstetric Labor Complications</condition>
  <condition>Pregnancy Complications</condition>
  <condition>Physiological Effects of Drugs</condition>
  <condition>Uterine Cervical Incompetence</condition>
  <condition>Anti-Bacterial Agents</condition>
  <condition>Azithromycin</condition>
  <condition>Cefazolin</condition>
  <arm_group>
    <arm_group_label>Cefazolin and Indomethacin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Control arm- perioperative cefazolin and indomethacin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Azithromycin + control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>perioperative azithromycin, cefazolin and indomethacin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin 1 gram IV</intervention_name>
    <description>Perioperative addition of azithromycin at the time of physical exam indicated cerclage placement.</description>
    <arm_group_label>Azithromycin + control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefazolin and indomethacin</intervention_name>
    <description>Perioperative standard of care with cefazolin and indomethacin</description>
    <arm_group_label>Azithromycin + control</arm_group_label>
    <arm_group_label>Cefazolin and Indomethacin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pregnant women with singleton pregnancies&#xD;
&#xD;
          -  â‰¥18 years old&#xD;
&#xD;
          -  Estimated gestational age less than 24 weeks&#xD;
&#xD;
          -  Meet criteria for an exam indicated cerclage&#xD;
&#xD;
          -  Patients must also be able to provide consent, demonstrate an understanding of the&#xD;
             purpose of the study, and agree to the study protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV) positive status&#xD;
&#xD;
          -  Known prolonged QT syndrome&#xD;
&#xD;
          -  Major fetal congenital anomalies&#xD;
&#xD;
          -  Temperature of 100.4 F or higher&#xD;
&#xD;
          -  Prior cerclage during the current pregnancy&#xD;
&#xD;
          -  Contraindication to indomethacin&#xD;
&#xD;
          -  Allergy to both penicillin and clindamycin&#xD;
&#xD;
          -  Received indomethacin or any antibiotics within 7 days before their presentation&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jenani S Jayakumaran, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jenani S Jayakumaran, MD</last_name>
    <phone>2159555000</phone>
    <email>jenani.jayakumaran@jefferson.edu</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 25, 2021</study_first_submitted>
  <study_first_submitted_qc>November 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cerclage</keyword>
  <keyword>preterm birth</keyword>
  <keyword>premature cervical dilation</keyword>
  <keyword>antibiotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Pregnancy Complications</mesh_term>
    <mesh_term>Obstetric Labor Complications</mesh_term>
    <mesh_term>Obstetric Labor, Premature</mesh_term>
    <mesh_term>Uterine Cervical Incompetence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
    <mesh_term>Cefazolin</mesh_term>
    <mesh_term>Indomethacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

